Vessi Medical takes a new approach to treat superficial bladder cancer. The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.
The market seeks an effective treatment for superficial bladder cancer that offers reduced recurrence rates, improved patient outcomes, and lower health care costs.
Vessi Medical takes a new approach in the treatment of superficial bladder cancer. The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue. The Vessi Medical system consists of a standalone console and a disposable catheter that is inserted into the bladder similarly to existing intravesical techniques.
Currently, dermatologists and gynecologists use surface cryotherapy extensively, and it has been known to be highly effective in destroying surface lesions.
Founded: Joined Trendlines Medical July 2017
Stage: Technology development
Investor: The Trendlines Group
IP: National phase and provisional
Non-muscle-invasive bladder cancer (NMIBC), also known as superficial bladder cancer, is found on the surface of the inside lining of the bladder, and accounts for ~75% of new patients with bladder cancer. In cases of high-risk superficial bladder cancer, treatment involves intravesical (inside the bladder) therapy in which an immunotherapy or chemotherapy drug is inserted directly into the bladder via a catheter. These therapy modalities cause severe side effects and have limited outcomes. Unfortunately, due to high recurrence rates, many patients undergo bladder removal.
Reports state that bladder cancer has the highest cost per patient of all cancers, and that 43% of all bladder removals begin with superficial cancer (European Association of Urology. 2012. Guidelines on Bladder Cancer Muscle-invasive and Metastatic.)
At any point in time, an estimated 3 million people worldwide have a history of bladder cancer. The World Cancer Research Fund International estimates there are about 430,000 new bladder cancer cases worldwide each year. In the U.S. alone, about 79,000 new cases are diagnosed annually (American Cancer Society).
The Company estimates its global market potential at over $1 billion annually.
Cryotherapy for superficial bladder cancer
Eyal Kochavi, CEO
Wireless, wearable vital sign monitoring system
Endoscopic ultrasound fine needle biopsy
Portable, automatic system for peritoneal dialysis
Device for treating ischemic stroke
Anastomotic closure device for laparoscopic bowel resection
Miniature screwless implant for facet joint fusion